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Hereditary nonpolyposis colorectal cancer (HNPCC) accounts for ∼2% of all colorectal cancer (CRC) cases and
is the most common hereditary CRC syndrome. We have previously reported a high incidence of microsatellite
instability (MSI) and germline mismatch repair (MMR) gene mutations in young Hong Kong Chinese with CRC.
Ongoing studies at the Hereditary Gastrointestinal Cancer Registry in Hong Kong have revealed a unique germline
MSH2 c.1452–1455delAATG mutation that has not been reported in other ethnic groups. Detailed analysis showed
that this speciﬁc MSH2 mutation constituted 21% of all germline MMR gene mutations and 36% of all MSH2
germline mutations identiﬁed. We designed a speciﬁc PCR-based diagnostic test on parafﬁn-embedded tissues and
identiﬁed this germline mutation in 2 (1.5%) of 138 consecutive patients with early-onset CRC (!46 years of age
at diagnosis). Haplotype analysis was performed using 11 microsatellite markers located between D2S391 and
D2S123. All 10 families had the same disease haplotype, suggesting a founder effect. These 10 families all originated
from the Chinese province of Guangdong, which historically included Hong Kong. It is the most populous of the
Chinese provinces, with a population of 193 million. Further analysis suggested that this founder mutation may
date back to between 22 and 103 generations ago. The identiﬁcation of this MSH2 founder mutation has important
implications for the design of mutation-detection strategies for the southern Chinese population. Since there were
major emigrations from Hong Kong and Guangdong province during the 19th and 20th centuries, this ﬁnding is
also signiﬁcant for Chinese communities worldwide.
Hereditary nonpolyposis colorectal cancer (HNPCC)
(MIM #114500) accounts for ∼2% of all colorectal can-
cer (CRC) cases (Aaltonen et al. 1998) and is the most
common hereditary CRC syndrome. Germline mutations
in the six DNA mismatch repair (MMR) genes, including
MSH2, MLH1, MSH6, PMS1, PMS2, and MLH3, have
been identiﬁed in kindreds withHNPCC, and inactivation
of the MMR mechanism contributes to the microsatellite
instability (MSI) phenotype detected in HNPCC tumors.
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Mutations in two of these MMR genes, MSH2 and
MLH1, account for the majority of the kindreds with
HNPCC (International Collaborative Group on HNPCC
[ICG-HNPCC]) (Peltomaki 2001).
CRC is the second most common cancer in Hong
Kong. We recently drew attention to the distinct epi-
demiology in the Hong Kong Chinese population, in
which there is an incidence rate of CRC in the young
population (!46 years of age at diagnosis) that is four
times the rate in other countries, such as the United
States, Scotland, and Japan (Yuen et al. 1997). To further
clarify the origin of this apparent population suscepti-
bility, we have studied the incidence of MSI and MMR
gene mutations in relation to age at onset of patients
with CRC. The results showed that a signiﬁcant pro-
portion of tumors from young patients exhibited high-
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Figure 1 A, Diagnostic PCR test for the MSH2 c.1452–1455delAATG mutation. The parafﬁn sections, prepared from stored blocks, were
assessed by light microscopy. Areas with the tumor or normal colonic mucosa were microdissected under a light microscope for DNA extraction
by use of standard protocol. The primer sequences were as follows: forward primer CATTTGATCCTAATCTCAGTGAA; reverse primer
CAAGATCTCTGGCTGCACTT. Forty cycles of PCR were performed in 20 ml with 2 ml–3 ml of DNA lysate from parafﬁn-embedded tissue,
1 # PCR buffer, 2 mM MgCl2, 4 pmol each of forward and reverse primer, 50 mM of each dNTP, and 0.1 U Platinum Taq polymerase
(Invitrogen). The annealing temperature was 60C. The PCR products were electrophoresed in 6% polyacrylamide (upper panel) or 3% agarose
gels (lower panel). Lane 1 shows the negative control from an individual without the speciﬁc MSH2 mutation. Lane 2 indicates the positive
control from an individual with the speciﬁc MSH2 mutation, showing an upper heteroduplex band, a middle wild-type band (90 bp), and a
lower deletion mutant band (86 bp); M represents the 10-bp ladder. Lanes 3 and 4 show PCR amplicons from the parafﬁn-embedded nontumor
colonic tissues of the two young patients who screened positive for the speciﬁc MSH2 mutation. Lanes 5 and 6 indicate PCR amplicons from
genomic DNA of two family members of the patient in lane 4. Lanes 7 and 8 illustrate PCR amplicons from parafﬁn-embedded tissues of other
young patients with CRC but without the speciﬁc mutation. B, Direct DNA sequencing of the PCR products ampliﬁed from DNA extracted
from parafﬁn-embedded tissue of patient in lane 4 of ﬁgure 1A. The top panel illustrates the overlapping sequence after the point of deletion
in microdissected normal tissue. The lower panel indicates the complete loss of the wild-type sequence in the microdissected tumor sample. The
arrowhead denotes the site of the AATG deletion.
level MSI and that many of them had a germline mu-
tation in one of the MMR genes; thus, these patients
did, in fact, exhibit HNPCC (Chan et al. 1999; Ho et
al. 2000; Yuen et al. 2002). In addition, we have iden-
tiﬁed a founder mutation characterized by a 1.8-kb de-
letion that includes exon 11 in MLH1 in two unrelated
Chinese families with HNPCC (Chan et al. 2001). The
identiﬁcation of founder mutations is not just of interest
to researchers but has important implications in the de-
sign of mutation-detection strategies for ethnic popu-
lations. Previous identiﬁcation of two founder MLH1
mutations in the Finnish population and three founder
BRCA1/2 mutations in the Ashkenazi Jewish population
have facilitated the genetic diagnosis in these popula-
tions (Nystrom-Lahti et al. 1995; Moisio et al. 1996;
Shiri-Sverdlov et al. 2000).
In our previous studies, we observed a recurrent
MSH2 c.1452–1455delAATG germline mutation that
had not been reported in other ethnic groups (Chan et
al. 1999; Yuen et al. 2002). Therefore, we examined the
incidence of this germline MMR gene mutation in our
Hereditary Gastrointestinal Cancer Registry, which is
the only registry in Hong Kong that provides compre-
hensive service, including genetic diagnosis, for families
with hereditary CRC syndromes (Hereditary Gastroin-
testinal Registry Hong Kong). The genetic diagnostic
laboratory of the registry has established standard pro-
tocols for genetic diagnosis. The MSI status of the tumor
was determined using a panel of 6–10 microsatellite
markers. MSH2 and MLH1 protein expression was
studied using immunohistochemical staining. Mutations
were detected using a combination of in vitro synthesized
protein (IVSP) assay, RT-PCR, and direct DNA sequenc-
ing methods. Details of these methodologies have been
described in our previous studies (Leung et al. 1998;
Chan et al. 1999; Chan et al. 2001; Yuen et al. 2002).
Up to the end of 2002, the Registry had recorded 13
MLH1, 22 MSH2, and 3 MSH6 germline mutations. Of
the 22 MSH2 germline mutations, 8 (36.4%) were
c.1452–1455delAATGmutations. In all of these cancers,
there was high-level MSI, and immunohistochemical
staining showed loss of MSH2 protein. A truncated
MSH2 protein product could be detected by IVSP, and
the speciﬁc germline MSH2 mutation was conﬁrmed by
direct DNA sequencing.
To explore the frequency of this germline MSH2 mu-
tation in our population, 143 consecutive archival for-
malin-ﬁxed parafﬁn-embedded CRC resection speci-
mens, from patients whose age at diagnosis was !46
years, were retrieved from the pathology departments of
three regional hospitals. DNA from tumor tissue and
normal tissue was extracted by microdissection from
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Figure 2 Map of China, with Guangdong province highlighted.
The stars denote the locations of the counties/cities from which six of
the families with the MSH2 c.1452–1455delAATG mutation in our
study originated. In the four remaining families, the exact counties/
cities of origin in Guangdong province are not known.
parafﬁn sections. A diagnostic PCR test was designed
by ampliﬁcation of a 90-bp fragment covering the de-
leted region. Cases with the MSH2 c.1452–1455del-
AATG mutation showed a speciﬁc banding pattern by
gel electrophoresis, with the presence of three bands that
corresponded to heteroduplex, homozygous wild-type
(90 bp in length), and homozygous mutant fragments
(86 bp in length), respectively. DNA was successfully
ampliﬁed by this PCR-based method from 138 cases.
Two patients (1.5%) showed an abnormal banding pat-
tern, as seen in the positive control (ﬁg. 1A). Direct DNA
sequencing conﬁrmed the presence of MSH2 c.1452–
1455delAATG in both the tumors and the normal tissues
of these two patients (ﬁg. 1B). In addition, one of the
tumors had lost the wild-type allele.
We then analyzed the detailed family histories of pa-
tients carrying this speciﬁc germline mutation. These
were obtained using both in-person and telephone in-
terviews with the patients and their relatives, as de-
scribed previously (Chan et al. 1999; Ho et al. 2000).
The majority of these families have strong family or
personal history of cancer. A total of 43 cancers were
noted in these families: 29 CRCs, 4 uterine cancers, 4
brain tumors, 2 breast cancers, 1 ovarian cancer, 1 stom-
ach cancer, and 2 disseminated cancers of unknown or-
igin. The majority of these cancers were diagnosed be-
fore the age of 50 years. Although these families did
have multiple individuals with a history of cancer, only
three families (H041, H043, and H046) satisﬁed the
Amsterdam criteria/Bethesda criteria I. FamilyH004 sat-
isﬁed the Amsterdam II criteria. Family H004 and four
others (H032, H037, H061, and H073) satisﬁed Be-
thesda criteria II and/or III (Rodriguez-Bigas et al. 1997).
For the remaining three individuals (from familiesH037,
H072, and W043), the family history could not be
traced.
These individuals and their families were interviewed
further to explore the possibility of the existence of kin-
ship among them. Documented family histories indi-
cated that the most ancient and traceable ancestors of
these families did not have any blood relationship to one
another. They all originated from the Guangdong prov-
ince of southern China, which is the origin of most Hong
Kong inhabitants. Further inquiries revealed that the an-
cestors of these patients originally resided in at least ﬁve
different counties/regions within Guangdong province
(ﬁg. 2).
Whenever possible, members from two generations
were invited for haplotype analysis. Venous blood was
sampled, with informed consent, for DNA extraction by
use of standard protocols. Of the 10 families with this
speciﬁc MSH2 germline mutation, many are small fam-
ilies, and, for cultural reasons, the older generationswere
reluctant to give consent for genotype analysis. There-
fore, there were only two families (H046 and H073)
with DNA available from members of two consecutive
generations. To estimate the frequency of the disease
haplotype in the general population, 51 genomic DNA
samples from two consecutive generations of 23 families
(5 families with both parents and one descendant; 18
families with either the father or mother and one de-
scendant) without this MSH2 mutation were used as
the control population. Initially, seven microsatellite
markers (Tel-D2S119-D2S391-MSH2-D2S123-D2S378-
D2S386-D2S147-D2S136-Cen) were selected from the
Genethon genetic map on the basis of information from
UniSTS database of the National Center for Biotech-
nology Information (NCBI). These markers have also
been recorded in a single human genome contig (Gen-
Bank accession number NT_022184). Their order and
their physical position in relation to the location of the
speciﬁc 4-bp deletion in exon 9 of MSH2 are listed in
ﬁgure 3. By use of these seven markers, we determined
that the disease haplotype for family H046 was 2-2-10-
2-2-1-2, whereas for family H073 the haplotype was 1-
2-9-1-2-1-1. Comparison of the two disease haplotypes
showed a low level of linkage disequilibrium, which
might be due to the fact that these markers were far
away from the mutation site.
Eleven microsatellite markers located between
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Figure 3 Schematic representation of MSH2 and the surrounding regions of chromosome 2. This map is based on the information provided
by UniSTS, NCBI. The location and order of the loci used in the present study, as well as their physical and genetic positions with reference
to the MSH2 c.1452–1455delAATG mutation site, are shown. These data are extracted from the Genethon map, the Marshﬁeld genetic map
(Marshﬁeld Center for Medical Genetics), and the contig NT_022184.
D2S391 and D2S123 were further selected. These in-
cluded three tetranucleotide repeats (P50, P51, and P55)
and three dinucleotide repeats (P22, P26, and P27),
which had been used elsewhere for MSH2 haplotype
analysis (Desai et al. 2000), as well as ﬁve novel dinu-
cleotide repeats (P11, P48, P58, P59, and P61). The
physical locations of these microsatellite markers in re-
lation to MSH2, as deﬁned by the human genome contig
NT_022184, are also shown in ﬁgure 3. By use of this
second set of 11microsatellite markers spanning a region
of 3.3 cM, ﬂanked by D2S391 and D2S123, the same
disease haplotype (5-2-1-1-1-5-2-1-2-1-3) (ﬁg. 4) was
identiﬁed for both family H046 and family H073.
Genotype analysis was performed using both sets of
markers for the remaining eight families, and the hap-
lotypes were reconstructed by PHASE (Stephens et al.
2001), which used Bayesian methods to predict the hap-
lotype distribution, conditional on observed genotypes.
Again, linkage disequilibrium was not signiﬁcant when
the ﬁrst set of seven Genethon markers was used. With
the second set of 11 microsatellite markers, seven of the
eight families revealed an identical disease haplotype to
that found in families H046 and H073 (ﬁg. 4). For the
last family (H061), a mutation in the marker P27 was
present, resulting in an unmatched haplotype. When this
locus was ignored, an identical haplotype could be re-
constructed as the consensus disease haplotype (ﬁg. 4).
The allele frequencies of the 11 microsatellite loci on
the mutation-bearing ( ) and control ( )np 10 np 74
chromosomes are listed in table 1. Compared with the
control chromosomes, allele frequencies of all of these
loci on the disease haplotype were in excess of the fre-
quencies on the mutation-bearing chromosomes. More-
over, the disease haplotype was not found in any of the
74 haplotypes from the 23 parent/child-pair control pop-
ulation. These data suggest that this germline MSH2
c.1452–1455delAATG mutation is a founder mutation
in the southern Chinese population.
For age estimation of this founder mutation, allele-
frequency distributions of the individual markers in dis-
ease and control chromosomes were compared using the
Mantel-Haenszel common odds ratio estimate. The link-
age disequilibrium for the 13 microsatellite loci was cal-
culated according to the method employed by Bengtsson
and Thomson (1981). On the basis of the recombination
fraction and the linkage disequilibrium of loci D2S391
and D2S123, the age of the disease haplotype was cal-
culated to be between 22 and 103 generations (Risch et
al. 1995) (table 1).
Up to the end of 2003, 695 germline mutations were
Reports 1039
Figure 4 Disease haplotypes of the 10 families with the speciﬁc MSH2 mutation. Haplotype analysis was performed as described elsewhere
(Chan et al. 2001). The regions covering these microsatellite markers were ampliﬁed by PCR by use of ﬂuorescent dye-labeled M13(21)-
tagged forward primers. The PCR amplicons were analyzed using the automated 377 DNA Sequencer (Applied Biosystems) with the GeneScan
program. Alleles were numbered consecutively according to increasing size. The initial eight families with the speciﬁc MSH2 mutation are
shown on the left; the two families screened positive by the PCR-based diagnostic method are shown on the right. Also shown are the phased
disease haplotype (gray), the reconstructed disease haplotype (blue), loci not ampliﬁable from parafﬁn tissues (black), and the observable
recombination events (pink).
recorded in the ICG-HNPCC database. Mutations of
MSH2, MLH1, and MSH6 account for 38.7%, 56.5%
and 4.7% of all germline mutations, respectively. Our
present study reported a frequent germline MSH2
c.1452–1455delAATGmutation in the southernChinese
population. This particular mutation was not found
among the 269 cases of MSH2 mutations in the ICG-
HNPCC database. Haplotype analysis suggested that it
was a founder mutation that occurred between 22 and
103 generations ago.
Founder mutations in MMR genes explain a substan-
tial fraction of instances of HNPCC in some ethnic
groups. In Finland, two mutations in MLH1 (a 3.5-kb
genomic deletion that includes exon 16 and a splice-
acceptor site mutation of exon 6) account for 63% of
all disease-causing mutations in families with HNPCC
(Nystrom-Lahti et al. 1995). Hutter et al. described a
third founder MLH1 mutation (MLH1 c.2141GrA) in
several apparently unrelated families in the Valais region
of Switzerland (Hutter et al. 1996). We also identiﬁed
a founder mutation ofMLH1 (a 1.8-kb genomic deletion
that includes exon 11) in two apparently unrelated
southern Chinese families (Chan et al. 2001). TheMSH2
IVS53ArT mutation has been observed in families
with HNPCC of many different populations and ac-
counts for 14% of all known pathogenic MSH2 mu-
tations. Whereas families in Newfoundland, Canada,
have been found to share a common disease haplotype,
those from other countries, such as the United States,
England, Italy, Japan, and Hong Kong, do not, and the
mutation appears to arise de novo (Froggatt et al. 1999;
Desai et al. 2000). More recently, two MSH2 founder
mutations (MSH2 c.1906GrC and MSH2 deletion of
exons 1–6) were recorded to account for one-third of
families with HNPCC in Ashkenazi Jews and one-tenth
of American families with HNPCC, respectively (Foul-
kes et al. 2002;Wagner et al. 2003). Our current ﬁndings
have provided evidence for another founder mutation of
MSH2 that is important in the Chinese population. From
our own Registry database, we determined that this mu-
tation accounts for 21% of all pathogenic germline
MMR mutations and 36% of MSH2 mutations detected
so far. The identiﬁcation of founder mutations in MMR
genes has practical implications, in that ethnic-speciﬁc
mutation-screening strategies should be employed before
a more general search for pathogenic mutations is un-
dertaken. Indeed, by use of this approach, another three
unrelated young patients with CRC who harbored this
MSH2 founder mutation were recently identiﬁed during
the preparation of this manuscript.
The existence of these ethnic-speciﬁc founder muta-
tions may contribute variably to the general overall in-
cidence of CRC. For example, MSH2 c.1906GrC was
found in 2%–3% of early-onset CRCs in the Ashkenazi
Jewish population (Foulkes et al. 2002). In Hong Kong,
our previous epidemiology study identiﬁed a high inci-
dence of early-onset CRC, as compared with other coun-
tries (Yuen et al. 1997). To date, 10%–12% of all CRCs
in Hong Kong occur in individuals !46 years of age
(Hong Kong Cancer Registry). We show here that 1.5%
of these early-onset CRCs are related to this particular
founder mutation. It remains to be seen whether a cu-
mulative effect of founder mutations of various cancer-
susceptibility genes with different penetrances may con-
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Table 1
Linkage Disequilibrium between the D2S391 and D2S123 Markers and Age Estimation of the Founder MSH2 c.1452–
1455delAATG Mutation
MARKER
ALLELE
SIZE
(bp)
FREQUENCY FOR
MARKER ALLELE ON
LD
(d)
PHYSICAL
DISTANCE
(kb)
GENETIC
DISTANCE
(cM)
RECOMBINATION
FRACTION
(v)
ESTIMATED
AGE
(generations)
Mutation-Bearing
Chromosomes
Normal
Chromosomes
D2S391 183 .556 (5/9) .284 (21/74) .379 1,278.587 .935 .009352 103
P11 190 1.000 (10/10) .405 (30/74) 1.000 124.911 .091 .000914 …
P50 302 1.000 (9/9) .761 (54/71) 1.000 53.895 .039 .000394 …
P51 270 1.000 (9/9) .257 (19/74) 1.000 30.635 .022 .000224 …
P55 205 1.000 (9/9) .357 (25/70) 1.000 25.726 .019 .000188 …
P48 144 1.000 (10/10) .716 (53/74) 1.000 10.084 .007 .000074 …
P27 160 .900 (9/10) .459 (34/74) … 110.929 .081 .000811 …
P26 166 1.000 (10/10) .378 (28/74) 1.000 114.423 .084 .000837 …
P22 263 1.000 (9/9) .620 (44/71) 1.000 136.940 .100 .001002 …
P58 156 1.000 (10/10) .284 (21/74) 1.000 175.654 .128 .001285 …
P59 210 1.000 (8/8) .391 (27/69) 1.000 178.198 .130 .001303 …
P61 160 1.000 (8/8) .324 (24/74) 1.000 201.307 .147 .001472 …
D2S123 160 .556 (5/9) .000 (0/74) .556 3,598.226 2.632 .026317 22
NOTE.—The linkage disequilibrium (LD) index was calculated according to Bengtsson and Thomson (1981): dp(PdPn)/(1Pn),
where Pd and Pn are the frequencies for the marker allele on mutation-bearing and normal chromosomes, respectively. The physical
and genetic distances are expressed with reference to the speciﬁc MSH2 mutation site. The appropriate physical-to-genetic distance
conversion factor was calculated by linear regression analysis of genetic versus physical map position by use of seven markers in
proximity to MSH2, with known centimorgan (cM) (Genethon and Marshﬁeld maps) and megabase (Mb) (UniSTS, NCBI) infor-
mation, as highlighted in ﬁgure 3. The conversion factor was calculated to be 0.7314 cM/Mb (using data from Genethon), which
compared well with that from the Marshﬁeld genetic map (0.7342) (using data from the Marshﬁeld Center for Medical Genetics).
The Kosambi’s function (Colombo et al. 2000) was applied to convert the genetic map distance into the recombination fraction (v).
Estimation of the age of the mutation was based on the following formula (Risch et al. 1995): generations p logd/log(1v).
tribute to the observed high incidence of early-onset
CRC in our population.
The signiﬁcance of our ﬁnding is not limited to Hong
Kong locally. All 10 families carrying the founder mu-
tation originated from the Guangdong province in
China, which is in the immediate vicinity of Hong Kong.
Guangdong (also known as Canton) province has an
area of 177,600 km2 and a total population size of 86.42
million (National Bureau of Statistics of China). His-
torically, Hong Kong was part of Guangdong province,
and the ancestors of the majority of current Hong Kong
residents were from Guangdong. Thus, together with the
6.8 million inhabitants in Hong Kong, Guangdong has
the largest provincial population size, with 193 million
people. Several major emigration waves from Guang-
dong and Hong Kong in the 19th and 20th centuries
led to the establishment of large Chinese communities
in the United States, Canada, Australia, and the United
Kingdom (Chinn 1969; Hoexter 1976) (Canada’s Dig-
ital Collections; Chinese Museum [Australia]; The Chi-
nese in New Zealand; Library of Congress [United
States]). Since we have noticed this founder effect in
Hong Kong, we believe its effects may be seen in other
Chinese communities of Guangdong descent as well.
Our local experience in the Registry shows that many
of these emigrants have lost contact with their relatives
and extended families in mainland China. At times, it
is difﬁcult, if not impossible, to have a comprehensive
family medical history, thus making a ﬁrm clinical di-
agnosis of HNPCC challenging. Similar to our previous
reports (Chan et al. 1999; Yuen et al. 2002), most of
the families studied here with this germline mutation do
not have a family history that satisﬁes the Amsterdam
criteria. Thus, our ﬁndings have important implications
for the design of mutation-detection strategies for
HNPCC in the southern Chinese population worldwide.
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